OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Schweizer on the Rationale for the CARD Trial in mCRPC

December 21st 2020

Michael Schweizer, MD, discusses the rationale for the phase 3 CARD trial in metastatic castration-resistant prostate cancer.

Dr. Jain on the Role of BTK Inhibitors in MCL

December 21st 2020

Preetesh Jain, MD, PhD, discusses the role of BTK inhibitors in mantle cell lymphoma.

Dr. Agarwal on Remaining Challenges With Abiraterone in mCSPC

December 21st 2020

Neeraj Agarwal, MD, discusses remaining challenges with abiraterone acetate in metastatic castration-sensitive prostate cancer.

Dr. Shore on the FDA Approval of Relugolix in Advanced Prostate Cancer

December 18th 2020

Neal D. Shore, MD, FACS, discusses the approval of relugolix in advanced prostate cancer.

Dr. Braunstein on the Expanding Armamentarium in Multiple Myeloma

December 18th 2020

Marc J. Braunstein, MD, PhD, discusses the expanding treatment armamentarium in multiple myeloma.

Dr. Patel on Findings From the NAPOLI-1 Trial in Pancreatic Cancer

December 18th 2020

Reema A. Patel, MD, discusses findings from the NAPOLI-1 trial in pancreatic cancer.

Dr. Kasi on Findings From the CRC-MRD Consortia in CRC

December 18th 2020

Pashtoon M. Kasi, MD, MS, discusses findings from the CRC-MRD Consortia in colorectal cancer.

Dr. Bahary on the Role of Pemigatinib in Biliary Tract Cancers

December 18th 2020

Nathan Bahary, MD, PhD, discusses the role of pemigatinib in biliary tract cancers.

Dr. Rifkin on Corneal Toxicities With Belantamab Mafodotin in Multiple Myeloma

December 17th 2020

Robert M. Rifkin, MD, FACP, discusses corneal toxicities with belantamab mafodotin-blmf in multiple myeloma.

Dr. Mohyuddin on Improving Survival in Multiple Myeloma

December 17th 2020

Ghulam Rehman Mohyuddin, MD, discusses improving survival for patients with multiple myeloma.

Dr. Verstovsek on the Role of Ruxolitinib in Myelofibrosis

December 16th 2020

Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in myelofibrosis.

Dr. Hurwitz Compares the Utility of Antiandrogens in Nonmetastatic CRPC

December 16th 2020

Michael E. Hurwitz, MD, PhD, compares the utility of antiandrogens in nonmetastatic castration-resistant prostate cancer.

Dr. Grothey on the Role of Precision Medicine in CRC

December 16th 2020

Axel Grothey, MD, discusses the role of precision medicine in colorectal cancer.

Dr. Samur on the Evolving Treatment Landscape in Multiple Myeloma

December 16th 2020

Mehmet K. Samur, PhD, discusses the evolving treatment landscape in multiple myeloma.

Dr. Price on the Rationale for Sotorasib in Advanced Gastrointestinal Cancers

December 16th 2020

Timothy Price, MBBS, DHthSc, FRACP, discusses the rationale to evaluate sotorasib in gastrointestinal cancers.

Dr. Sznol on the Challenges of Managing Immune-Related Toxicities in Melanoma

December 16th 2020

Mario Sznol, MD, discusses the challenges of managing immune-related toxicities in melanoma.

Dr. Shah on the Importance of Assessing Quality of Life in Multiple Myeloma

December 15th 2020

Nina Shah, MD, discusses the importance of assessing quality of life in multiple myeloma.

Dr. Hobbs on Managing Ponatinib-Associated Toxicities in CML

December 15th 2020

Gaby Hobbs, MD, discusses managing ponatinib-associated toxicities in chronic myeloid leukemia.

Dr. Atkins on the Benefits of Neoadjuvant Therapy in Melanoma

December 15th 2020

Michael B. Atkins, MD, discusses the benefits of neoadjuvant therapy in melanoma.

Dr. Sweet on Treatment Selection With TKIs in CML

December 15th 2020

Kendra Sweet, MD, discusses treatment selection with TKIs in chronic myeloid leukemia.